Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis

[eng] The fact that TREX2 is specifically expressed on KCs, upregulated in psoriatic skin and its loss leads to a decreased inflammation in mice models of the disease, points TREX2 as a candidate target for new KC-based PsO therapies. We hypothesize that the inhibition of TREX2 can be as effective a...

Descripción completa

Detalles Bibliográficos
Autor: Filgaira Enri, Ingrid
Tipo de recurso: tesis doctoral
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:CBUC, CESCA
Repositorio:TDR. Tesis Doctorales en Red
OAI Identifier:oai:www.tdx.cat:10803/694013
Acceso en línea:http://hdl.handle.net/10803/694013
Access Level:acceso embargado
Palabra clave:Malalties de la pell
Enfermedades de la piel
Skin diseases
Psoriasi
Psoriasis
Dermatitis atòpica
Dermatitis atópica
Atopic dermatitis
Ciències de la Salut
616.5
id ES_950ca1dd5cd4f74397e6d8dc5a6d1f1e
oai_identifier_str oai:www.tdx.cat:10803/694013
network_acronym_str ES
network_name_str España
repository_id_str
spelling Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitisFilgaira Enri, IngridMalalties de la pellEnfermedades de la pielSkin diseasesPsoriasiPsoriasisDermatitis atòpicaDermatitis atópicaAtopic dermatitisCiències de la Salut616.5[eng] The fact that TREX2 is specifically expressed on KCs, upregulated in psoriatic skin and its loss leads to a decreased inflammation in mice models of the disease, points TREX2 as a candidate target for new KC-based PsO therapies. We hypothesize that the inhibition of TREX2 can be as effective as the most advanced available treatments, which mainly target the immune system, while avoiding their adverse broad immunosuppressive effects. Therefore, blocking TREX2 activity could be a promising non-immune and skin-specific approach to diminish KC-derived inflammation and avert the adverse side-effects associated to systemic treatments targeting the immune system. In this context, the global aim of the present PhD thesis was to identify, develop and characterize specific and effective TREX2 inhibitory compounds for PsO treatment and other TREX2-driven diseases and further determine their suitability and efficacy for future clinical trials. The specific goals were: 1. To identify and characterize specific, selective, potent and safe TREX2 inhibitory compounds to treat PsO. 2. To evaluate the role of TREX2 in AD and as therapeutic target in this disease. 3. To characterize the molecular mechanisms of TREX2 inhibitors.BiomedicinaUniversitat de BarcelonaSoler Prat, ConcepcióCiruela Alférez, FranciscoSoler Prat, ConcepcióUniversitat de Barcelona. Departament de Patologia i Terapèutica Experimental202520242025info:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/publishedVersion184 p.application/pdfhttp://hdl.handle.net/10803/694013TDX (Tesis Doctorals en Xarxa)reponame:TDR. Tesis Doctorales en Redinstname:CBUC, CESCAInglésADVERTIMENT. Tots els drets reservats. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs.info:eu-repo/semantics/embargoedAccessoai:www.tdx.cat:10803/6940132026-06-14T12:46:07Z
dc.title.none.fl_str_mv Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
title Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
spellingShingle Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
Filgaira Enri, Ingrid
Malalties de la pell
Enfermedades de la piel
Skin diseases
Psoriasi
Psoriasis
Dermatitis atòpica
Dermatitis atópica
Atopic dermatitis
Ciències de la Salut
616.5
title_short Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
title_full Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
title_fullStr Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
title_full_unstemmed Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
title_sort Targeting TREX2: an innovative keratinocyte-based therapy for psoriasis and atopic dermatitis
dc.creator.none.fl_str_mv Filgaira Enri, Ingrid
author Filgaira Enri, Ingrid
author_facet Filgaira Enri, Ingrid
author_role author
dc.contributor.none.fl_str_mv Soler Prat, Concepció
Ciruela Alférez, Francisco
Soler Prat, Concepció
Universitat de Barcelona. Departament de Patologia i Terapèutica Experimental
dc.subject.none.fl_str_mv Malalties de la pell
Enfermedades de la piel
Skin diseases
Psoriasi
Psoriasis
Dermatitis atòpica
Dermatitis atópica
Atopic dermatitis
Ciències de la Salut
616.5
topic Malalties de la pell
Enfermedades de la piel
Skin diseases
Psoriasi
Psoriasis
Dermatitis atòpica
Dermatitis atópica
Atopic dermatitis
Ciències de la Salut
616.5
description [eng] The fact that TREX2 is specifically expressed on KCs, upregulated in psoriatic skin and its loss leads to a decreased inflammation in mice models of the disease, points TREX2 as a candidate target for new KC-based PsO therapies. We hypothesize that the inhibition of TREX2 can be as effective as the most advanced available treatments, which mainly target the immune system, while avoiding their adverse broad immunosuppressive effects. Therefore, blocking TREX2 activity could be a promising non-immune and skin-specific approach to diminish KC-derived inflammation and avert the adverse side-effects associated to systemic treatments targeting the immune system. In this context, the global aim of the present PhD thesis was to identify, develop and characterize specific and effective TREX2 inhibitory compounds for PsO treatment and other TREX2-driven diseases and further determine their suitability and efficacy for future clinical trials. The specific goals were: 1. To identify and characterize specific, selective, potent and safe TREX2 inhibitory compounds to treat PsO. 2. To evaluate the role of TREX2 in AD and as therapeutic target in this disease. 3. To characterize the molecular mechanisms of TREX2 inhibitors.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/doctoralThesis
info:eu-repo/semantics/publishedVersion
format doctoralThesis
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10803/694013
url http://hdl.handle.net/10803/694013
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/embargoedAccess
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv 184 p.
application/pdf
dc.publisher.none.fl_str_mv Universitat de Barcelona
publisher.none.fl_str_mv Universitat de Barcelona
dc.source.none.fl_str_mv TDX (Tesis Doctorals en Xarxa)
reponame:TDR. Tesis Doctorales en Red
instname:CBUC, CESCA
instname_str CBUC, CESCA
reponame_str TDR. Tesis Doctorales en Red
collection TDR. Tesis Doctorales en Red
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413759710134272
score 15.81155

Similares en LA Referencia